Shareholder Tools

Press Releases

2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999
Press Releases
Date Title and Summary View
Dec 1, 2016 WEST LAFAYETTE, Ind., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that data from ongoing phase 1 trials of Endocyte's SMDC EC1456 will be presented at the IASLC 17th World Conference on ...
Nov 9, 2016 - Confirmed Maximum Dose for EC1169 and Initiated Expansion Phase in Prostate Cancer Patients - - First Confirmed RECIST Partial Response Observed in EC1169 Dose Escalation Reported at European Society for Medical Oncology (ESMO) in October -- Conference Call Today at 4:30 p.m. EST - WEST LAFAYETTE, Ind., Nov. 09, 2016 (GLOBE NEWSWIRE) --  End...
Nov 2, 2016 WEST LAFAYETTE, Ind., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 9th, at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast of...
Nov 1, 2016 WEST LAFAYETTE, Ind., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy today announced that the company's management team will present at the 25th Annual Credit Suisse Healthcare Conference on Tuesday, Nov. 8...
Oct 10, 2016 WEST LAFAYETTE, Ind., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, presented poster updates on its two lead clinical programs at the European Society for Medical Oncology (ESMO) 2016 Congress, being held...
Sep 29, 2016 WEST LAFAYETTE, Ind., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented at the European Society for Medical Oncology (ESMO), being held in Copenhagen, Denma...
Sep 20, 2016 WEST LAFAYETTE, Ind., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, Sept. ...
Aug 15, 2016 WEST LAFAYETTE, Ind., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that five posters will be presented by Endocyte scientists at the 252nd American Chemical Society (ACS) National Meeting...
Aug 9, 2016 WEST LAFAYETTE, Ind., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 16, a...
Aug 4, 2016 - Reached Maximum Tolerated Dose in Twice Weekly Dosing Schedule with EC1456 - - Initiating EC1456 Expansion Cohort in Targeted Population of Folate Receptor-Positive Non-Small Cell Lung Cancer Patients - - Data Presentations Expected for EC1456 and EC1169 in the Second Half of 2016 - - Conference Call Today at 4:30 p.m. EDT - WEST LAFAYETT...
1
... NextLast
Add to Briefcase = add release to Briefcase